ClinicalTrials.gg
RecruitingNCT07269717Updated May 11, 2026

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction

A Phase 2 interventional study of HRS-1893 Tablet and HRS-1893 Tablet Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 10
48 · median 69
Started
2026
with 3 others
Phase 2
3 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 4 that started in 2026, is one of 3 in phase 2, and was the 7th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 40 years at screening, regardless of gender;
  2. \< 35 kg/m²;
  3. Diagnosed with chronic heart failure before screening, and meeting relevant diagnostic criteria during the screening period: (1) Transthoracic echocardiography (TTE) at screening showing a resting (LVEF) ≥ 60%; (2) Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) during the screening period; (3) Echocardiography showing structural or functional abnormalities of the heart, etc.;
  4. (NYHA) classification of II or III at screening;
  5. KCCQ-CSS score between ≥25 and ≤75 at screening;
  6. Resting oxygen saturation >90% without supplemental oxygen at screening;
  7. Female participants of must have a negative serum pregnancy test before the first dose and must not be breastfeeding during the study. Female participants of childbearing potential and male participants whose partners are women of childbearing potential must agree to avoid donating sperm/eggs from the time of signing the until three months after the last dose of the study drug and comply with relevant requirements;
  8. Understand the study procedures and methods, voluntarily participate in this trial, and provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Previously diagnosed or found during screening with hypertrophic cardiomyopathy (HCM), or having infiltrative/genetic/storage diseases that cause heart failure with preserved (HFpEF)/myocardial hypertrophy (such as amyloidosis, Fabry disease, Noonan syndrome with left ventricular hypertrophy), or complete M protein or monoclonal light chain (such as κ or λ) detected in serum protein electrophoresis and serum immunofixation electrophoresis during screening (researchers may deem not applicable if amyloidosis/multiple myeloma are excluded);
  2. Previously diagnosed or found during screening with hyperthyroidism;
  3. At any time in their clinical history, previously experienced left ventricular systolic dysfunction (LVEF \<45%);
  4. History of syncope or sustained ventricular tachycardia within 6 months prior to screening;
  5. Previously experienced cardiac arrest with resuscitation at any time or received ICD therapy for life-threatening ventricular arrhythmia within 6 months prior to screening;
  6. Previously diagnosed or found during screening with atrial fibrillation;
  7. Coronary artery disease (stenosis >70% in one or more coronary arteries) or myocardial infarction: newly developed within 6 months prior to screening, or occurred more than 6 months prior without completed revascularization (such as percutaneous coronary intervention or coronary artery bypass grafting);
  8. Moderate to severe aortic stenosis, hemodynamically significant mitral stenosis, or severe mitral/tricuspid regurgitation at screening (as determined by the investigator);
  9. Severe (COPD) or other pulmonary diseases requiring home oxygen therapy, chronic nebulization/oral treatment, or hospitalization due to pulmonary decompensation in the past 12 months;
  10. Acute respiratory infection at screening;
  11. Required intravenous diuretics, inotropes, vasodilators, or left ventricular assist device therapy for acute decompensated heart failure within 30 days prior to screening;
  12. history of within the past 5 years (excluding cancers that have been confirmed cured or in remission for ≥5 years, basal or squamous cell skin cancer that was radically excised within 5 years, carcinoma in situ of the cervix, and excised colon polyps);
  13. abnormalities posing safety risks at screening (as determined by the investigator, such as second-degree type II AV block, complete AV block, symptomatic ventricular arrhythmias, torsades de pointes, etc.);
  14. Any clinically significant abnormal screening laboratory values during screening deemed unsuitable for enrollment by the investigator;
  15. Positive result in any infectious disease screening during screening, including surface antigen, antibody, syphilis antibody, antibody (or AIDS virus antibody or P24 antigen);
  16. Inability to complete the six-minute walk test during screening (e.g., due to leg fractures, post-stroke mobility impairment);
  17. Patients who received β-blockers, diltiazem, or verapamil prior to screening but were not on a stable dose for more than 4 weeks before randomization, or are expected not to maintain the same medication regimen during the trial;
  18. Subjects who received heart failure medication treatment (diuretics, sodium-glucose co-transporter 2 inhibitors [SGLT2i], angiotensin receptor-neprilysin inhibitors [ARNI], mineralocorticoid receptor antagonists [MRA], angiotensin-converting enzyme inhibitors [ACEI], angiotensin II receptor blockers [ARB], glucagon-like peptide-1 [GLP-1] or GLP-1/glucose-dependent insulinotropic polypeptide [GIP]) prior to screening but have not been on a stable dose for more than 4 weeks before randomization, or are expected to be unable to maintain the same medication regimen during the trial;
  19. Subjects who used a myosin inhibitor within a period shorter than 5 half-lives before the trial drug administration;
  20. Subjects who participated in any drug or medical device clinical trial within 3 months prior to screening (participation in a clinical trial is defined as the subject having received the trial drug or medical device treatment);
  21. Other conditions deemed by the investigator that make the subject unsuitable for participation in the trial, such as conditions that may increase trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the trial due to physiological or psychological diseases or conditions.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    HRS-1893 Tablet Group

    Drug: HRS-1893 Tablet

  • Placebo comparator
    HRS-1893 Tablet Placebo Group

    Drug: HRS-1893 Tablet Placebo

Interventions

  • HRS-1893 tablet.

  • DrugHRS-1893 Tablet Placebo

    HRS-1893 tablet placebo.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs).

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 24.

Secondary outcomes

  1. Change from baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP).

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 12 and Week 24.

  2. Change from baseline in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS).

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 12 and Week 24.

  3. Proportion of heart failure patients with preserved ejection fraction with an improvement of ≥1 NYHA functional class from baseline.

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 12 and Week 24.

  4. Change from baseline in total distance walked during the six-minute walk test (6MWT).

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 12 and Week 24.

  5. Change from baseline in resting left ventricular ejection fraction (LVEF).

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Week 12 and Week 24.

  6. Plasma concentration of HRS-1893.

    In heart failure patients with preserved ejection fraction after treatment with HRS-1893.

    Time frame: Up to about 29 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 8, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Mar 2027
CompletionEst.
May 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07269717
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Mar 30, 2026
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 11, 2026

Study contacts

Jianhong Lv
Contact
jianhong.lv.jl9@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion